Literature DB >> 16322460

Divergent immunoglobulin g subclass activity through selective Fc receptor binding.

Falk Nimmerjahn1, Jeffrey V Ravetch.   

Abstract

Subclasses of immunoglobulin G (IgG) display substantial differences in their ability to mediate effector responses, contributing to variable activity of antibodies against microbes and tumors. We demonstrate that the mechanism underlying this long-standing observation of subclass dominance in function is provided by the differential affinities of IgG subclasses for specific activating IgG Fc receptors compared with their affinities for the inhibitory IgG Fc receptor. The significant differences in the ratios of activating-to-inhibitory receptor binding predicted the in vivo activity. We suggest that these highly predictable functions assigned by Fc binding will be an important consideration in the design of therapeutic antibodies and vaccines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16322460     DOI: 10.1126/science.1118948

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  404 in total

1.  DNA vaccination in the skin using microneedles improves protection against influenza.

Authors:  Jae-Min Song; Yeu-Chun Kim; Eunju O; Richard W Compans; Mark R Prausnitz; Sang-Moo Kang
Journal:  Mol Ther       Date:  2012-04-17       Impact factor: 11.454

Review 2.  The role of sialic acid as a modulator of the anti-inflammatory activity of IgG.

Authors:  Sybille Böhm; Inessa Schwab; Anja Lux; Falk Nimmerjahn
Journal:  Semin Immunopathol       Date:  2012-03-22       Impact factor: 9.623

Review 3.  Mechanisms of IVIG efficacy in chronic inflammatory demyelinating polyneuropathy.

Authors:  Björn Tackenberg; Falk Nimmerjahn; Jan D Lünemann
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

Review 4.  A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs.

Authors:  Robert M Anthony; Jeffrey V Ravetch
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

5.  Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement.

Authors:  Fubin Li; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-20       Impact factor: 11.205

6.  STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy.

Authors:  Lekh N Dahal; Lang Dou; Khiyam Hussain; Rena Liu; Alexander Earley; Kerry L Cox; Salome Murinello; Ian Tracy; Francesco Forconi; Andrew J Steele; Patrick J Duriez; Diego Gomez-Nicola; Jessica L Teeling; Martin J Glennie; Mark S Cragg; Stephen A Beers
Journal:  Cancer Res       Date:  2017-05-16       Impact factor: 12.701

7.  Poly(I:C) adjuvant strongly enhances parasite-inhibitory antibodies and Th1 response against Plasmodium falciparum merozoite surface protein-1 (42-kDa fragment) in BALB/c mice.

Authors:  Akram Abouie Mehrizi; Niloufar Rezvani; Sedigheh Zakeri; Atefeh Gholami; Laleh Babaeekhou
Journal:  Med Microbiol Immunol       Date:  2018-02-03       Impact factor: 3.402

Review 8.  Immunological responses to influenza vaccination: lessons for improving vaccine efficacy.

Authors:  Taia T Wang; Stylianos Bournazos; Jeffrey V Ravetch
Journal:  Curr Opin Immunol       Date:  2018-05-10       Impact factor: 7.486

9.  Macrophages eliminate circulating tumor cells after monoclonal antibody therapy.

Authors:  Nuray Gül; Liane Babes; Kerstin Siegmund; Rianne Korthouwer; Marijn Bögels; Rens Braster; Gestur Vidarsson; Timo L M ten Hagen; Paul Kubes; Marjolein van Egmond
Journal:  J Clin Invest       Date:  2014-01-16       Impact factor: 14.808

Review 10.  TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells.

Authors:  Yoshikane Kikushige; Toshihiro Miyamoto
Journal:  Int J Hematol       Date:  2013-09-18       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.